We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

247 hedge funds and large institutions have $6.76B invested in BridgeBio Pharma in 2023 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 89 increasing their positions, 77 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 26

59% more capital invested

Capital invested by funds: $4.24B → $6.76B (+$2.51B)

50% more funds holding in top 10

Funds holding in top 10: 10 → 15 (+5)

22% more call options, than puts

Call options by funds: $110M | Put options by funds: $90.1M

16% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 77

12% more funds holding

Funds holding: 221 → 247 (+26)

2.95% less ownership

Funds ownership: 99.16% → 96.21% (-2.9%)

Holders
247
Holders Change
+26
Holders Change %
+11.76%
% of All Funds
3.6%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.22%
New
53
Increased
89
Reduced
77
Closed
26
Calls
$110M
Puts
$90.1M
Net Calls
+$20.2M
Net Calls Change
-$12.9M

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$69.2M
2
Morgan Stanley
Morgan Stanley
New York
+$56.2M
3
Goldman Sachs
Goldman Sachs
New York
+$55.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$45.8M
5
BlackRock
BlackRock
New York
+$27.2M

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$41.8M
2
CAM
Cormorant Asset Management
Massachusetts
-$39.6M
3
WP
Woodline Partners
California
-$25.1M
4
CS
Credit Suisse
Switzerland
-$19M
5
Renaissance Technologies
Renaissance Technologies
New York
-$15.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
101
Algert Global
California
$3.54M +$661K +22,012 +34%
EAM
102
Erste Asset Management
Austria
$3.52M +$481K +16,000 +23%
State of New Jersey Common Pension Fund D
103
State of New Jersey Common Pension Fund D
New Jersey
$3.5M +$138K +4,588 +6%
State of Wisconsin Investment Board
104
State of Wisconsin Investment Board
Wisconsin
$3.45M -$362K -12,062 -12%
EI
105
EAM Investors
California
$3.42M -$105K -3,488 -4%
DA
106
Duality Advisers
Florida
$3.24M +$932K +31,036 +63%
AAA
107
Affinity Asset Advisors
New York
$3.23M +$1.5M +50,000 +167%
Squarepoint
108
Squarepoint
New York
$3.23M -$2.63M -87,527 -52%
BC
109
BIT Capital
Germany
$2.97M +$2.02M +67,133 +1,056%
CAC
110
Cowen and Company
New York
$2.91M +$2.17M +72,141 New
New York State Common Retirement Fund
111
New York State Common Retirement Fund
New York
$2.76M +$608K +20,251 +42%
Mirae Asset Global Investments
112
Mirae Asset Global Investments
South Korea
$2.66M +$27.1K +904 +1%
EAM
113
Exome Asset Management
New York
$2.63M +$1.96M +65,113 New
ZP
114
Zimmer Partners
New York
$2.62M -$300K -10,000 -13%
IIM
115
Ironwood Investment Management
Massachusetts
$2.6M -$991 -33 -0.1%
MMA
116
Mizuho Markets Americas
New York
$2.6M -$485K -16,153 -20%
MIM
117
MetLife Investment Management
New Jersey
$2.44M – – –
AIG
118
American International Group
New York
$2.3M -$6.91K -230 -0.4%
SEI Investments
119
SEI Investments
Pennsylvania
$2.26M +$583K +19,405 +53%
Millennium Management
120
Millennium Management
New York
$2.25M -$12.3M -410,291 -88%
EP
121
Edgestream Partners
New Jersey
$2.03M +$1.06M +35,262 +234%
BMSSC
122
B. Metzler seel. Sohn & Co
Germany
$1.97M +$157K +5,213 +12%
Dimensional Fund Advisors
123
Dimensional Fund Advisors
Texas
$1.92M +$67.1K +2,234 +5%
Wells Fargo
124
Wells Fargo
California
$1.88M -$1.09M -36,312 -44%
PA
125
Profund Advisors
Maryland
$1.87M -$226K -7,522 -14%
3 4
5
6 7

BBIO Hedge Fund Activity: Q4 2023 in Review

247 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2023, worth a combined $6.76B — up 59% from $4.24B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new BBIO positions and 26 closed out — a net gain of 27 holders — while 89 added to existing stakes and 77 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $69.2M. The largest seller was HHLR Advisors, cutting an estimated $41.8M.

  • 247 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2023, up from 221 in Q3 2023.
  • Funds reported $6.76B of BridgeBio Pharma stock for Q4 2023, up 59% quarter-over-quarter.
  • 53 funds opened new BridgeBio Pharma positions in Q4 2023 and 26 closed out, a net change of +27 holders.
  • The largest BridgeBio Pharma buyer in Q4 2023 was Lord, Abbett & Co, an estimated $69.2M added.
  • The largest BridgeBio Pharma seller in Q4 2023 was HHLR Advisors, an estimated $41.8M sold.

Based on aggregated 13F filings for Q4 2023.